StockNews.com Begins Coverage on Pieris Pharmaceuticals (NASDAQ:PIRS)

Analysts at StockNews.com assumed coverage on shares of Pieris Pharmaceuticals (NASDAQ:PIRSGet Free Report) in a report issued on Wednesday. The firm set a “hold” rating on the biotechnology company’s stock.

Pieris Pharmaceuticals Stock Performance

Shares of NASDAQ PIRS opened at $13.60 on Wednesday. Pieris Pharmaceuticals has a fifty-two week low of $6.20 and a fifty-two week high of $22.32. The company has a market cap of $17.95 million, a PE ratio of -1.12 and a beta of 0.61. The business has a 50-day simple moving average of $16.09 and a two-hundred day simple moving average of $14.71.

Institutional Investors Weigh In On Pieris Pharmaceuticals

An institutional investor recently bought a new position in Pieris Pharmaceuticals stock. Frazier Life Sciences Management L.P. bought a new stake in Pieris Pharmaceuticals, Inc. (NASDAQ:PIRSFree Report) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 15,942 shares of the biotechnology company’s stock, valued at approximately $267,000. Frazier Life Sciences Management L.P. owned about 1.21% of Pieris Pharmaceuticals as of its most recent SEC filing. 40.11% of the stock is currently owned by institutional investors and hedge funds.

Pieris Pharmaceuticals Company Profile

(Get Free Report)

Pieris Pharmaceuticals, Inc, a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies.

Featured Articles

Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.